Date: 2012-11-28
Type of information: R&D agreement
Compound: Sprint™
Company: Beactica (Sweden) Janssen Research & Development - J&J (Belgium-USA)
Therapeutic area: undisclosed
Type agreement: R&D
collaboration
services
Action mechanism: Sprint™ is a SPR (surface plasmon resonance)-based small molecule drug discovery platform.
Disease: undisclosed
Details: Beactica, a Swedish fragment-based drug discovery company, has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the research services agreement, Beactica will use its proprietary drug discovery platform Sprint™ to identify novel allosteric modulators targeting undisclosed central nervous system (CNS) proteins of therapeutic interest to Janssen. Beactica initiated their first research services project with Janssen in early 2011.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
